These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16899108)

  • 81. The biology behind interleukin-6 targeted interventions.
    Liu X; Jones GW; Choy EH; Jones SA
    Curr Opin Rheumatol; 2016 Mar; 28(2):152-60. PubMed ID: 26751841
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Complement in the immunopathogenesis of rheumatic disease.
    Sturfelt G; Truedsson L
    Nat Rev Rheumatol; 2012 Aug; 8(8):458-68. PubMed ID: 22664835
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Anti-cytokine therapy for intractable hematologic diseases using monoclonal antibodies].
    Nishimoto N
    Nihon Naika Gakkai Zasshi; 2004 Feb; 93(2):390-6. PubMed ID: 15007951
    [No Abstract]   [Full Text] [Related]  

  • 84. [Chinese expert consensus on off-label use of Tocilizumab in rheumatic diseases].
    Committee of Chinese Primary Health Care Foundation for Rheumatologists and Immunologists
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(25):2308-2322. PubMed ID: 38951103
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The development of anticytokine therapeutics for rheumatic diseases.
    Arend WP; Goldring MB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S102-9. PubMed ID: 18240200
    [No Abstract]   [Full Text] [Related]  

  • 86. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.
    Li H; Tsokos GC
    Clin Rev Allergy Immunol; 2021 Feb; 60(1):31-45. PubMed ID: 33185790
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The Two-Faced Cytokine IL-6 in Host Defense and Diseases.
    Narazaki M; Kishimoto T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30423923
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Risk factor for hypofibrinogenemia induced by tocilizumab in rheumatic diseases.
    Bao Z; Xu X
    Clin Rheumatol; 2024 Oct; 43(10):3263-3264. PubMed ID: 39180611
    [No Abstract]   [Full Text] [Related]  

  • 89. Interleukin-6 as a therapeutic target in spondylarthritis: comment on the article by Tanaka et al.
    Wendling D
    Arthritis Care Res (Hoboken); 2010 May; 62(5):745; author reply 745-6. PubMed ID: 20191469
    [No Abstract]   [Full Text] [Related]  

  • 90. Therapeutic blockade of interleukin-6 in chronic inflammatory disease.
    Yamamoto K; Rose-John S
    Clin Pharmacol Ther; 2012 Apr; 91(4):574-6. PubMed ID: 22434029
    [No Abstract]   [Full Text] [Related]  

  • 91. Mixed effect of tocilizumab in spondylarthritis. Comments about the article by Wendling et al. entitled "Short-term effect of IL-6 inhibition in spondylarthritis". Joint Bone Spine 2010;77:624-5.
    Malochet-Guinamand S; Soubrier M
    Joint Bone Spine; 2012 Jan; 79(1):106; author reply 106-7. PubMed ID: 22041094
    [No Abstract]   [Full Text] [Related]  

  • 92. S100 proteins in rheumatic diseases.
    Austermann J; Spiekermann C; Roth J
    Nat Rev Rheumatol; 2018 Sep; 14(9):528-541. PubMed ID: 30076385
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The role of IL-33 in rheumatic diseases.
    Duan L; Chen J; Gong F; Shi G
    Clin Dev Immunol; 2013; 2013():924363. PubMed ID: 24151520
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor.
    Ueda O; Tateishi H; Higuchi Y; Fujii E; Kato A; Kawase Y; Wada NA; Tachibe T; Kakefuda M; Goto C; Kawaharada M; Shimaoka S; Hattori K; Jishage K
    Sci Rep; 2013; 3():1196. PubMed ID: 23378927
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.
    Kahlenberg JM
    Curr Opin Rheumatol; 2016 May; 28(3):197-203. PubMed ID: 26859478
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Tocilizumab: intestinal perforations.
    Prescrire Int; 2010 Oct; 19(109):216. PubMed ID: 21180379
    [No Abstract]   [Full Text] [Related]  

  • 97. IL-6 biology: implications for clinical targeting in rheumatic disease.
    Calabrese LH; Rose-John S
    Nat Rev Rheumatol; 2014 Dec; 10(12):720-7. PubMed ID: 25136784
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A bond between rheumatic diseases and cancer in the elderly: The interleukin-6 pathway.
    Iorio GC; Ammendolia A; Marotta N; Ricardi U; de Sire A
    Int J Rheum Dis; 2021 Oct; 24(10):1317-1320. PubMed ID: 34347374
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases.
    Harada A; Mukaida N; Matsushima K
    Mol Med Today; 1996 Nov; 2(11):482-9. PubMed ID: 8947914
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?
    Chizzolini C; Dayer JM; Miossec P
    Arthritis Res Ther; 2009; 11(5):246. PubMed ID: 19849823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.